ELCC 2023 | RET fusion-positive mNSCLC: selpercatinib and pralsetinib

Benjamin Besse, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses the treatment landscape of RET-fusion positive metastatic non-small cell lung cancer (NSCLC), touching on the recent approvals of selpercatinib and pralsetinib, associated efficacy and toxicity, as well as remaining questions on the development of resistance. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.